European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

High-risk PCa: Urological or radiation oncological approach

Tue, 15 Apr 2014

In the multidisciplinary Thematic Session 18, the urological and radiation oncological approaches to high-risk prostate cancer were discussed. The chairman of the session, Prof. Christian Stief (Munich, DE), introduced the debate by stating that the audience would hear “not necessarily opposing but merely different views on how to treat patients.”

Profs. Francesco Montorsi (Milan, IT) and Gert De Meerleer (Ghent, BE) defended surgical treatment and radiation therapy in high-risk prostate cancer, respectively. Montorsi started his presentation stating his conclusion: “We finally have the answer to the question of whether surgery or radiation therapy is better.”

Citing the recently published Sooriakumaran et al. study, Montorsi showed that radical prostatectomy improves overall survival, compared to radiation therapy. He added that extended lymph node dissection should be part of the procedure and adjuvant or salvage radiation therapy is an important additional treatment option for some patients.

In response, De Meerleer presented the oncological view. “Let me start by giving you my conflict of interest disclosure: I am a radiation oncologist,” he jokingly started. He acknowledged that this had been a bad year for radiation therapy, due in large part to the Sooriakumaran study.

He went on to say that the title of the study is misleading because the studied comparison is not really between surgery and radiation therapy. Since more than 60% of patients who underwent radical prostatectomy were also treated with radiation therapy, the actual comparison is between radiation therapy alone or in combination with surgery. De Meerleer urged for a change in terminology to prevent this type of misrepresentation.

Like Montorsi, De Meerleer stressed that lymph node dissection is important in this patient group. “I was taught that patients with enlarged lymph nodes are dead, but we should stop treating these patients as untreatable. The results after lymph node dissection are promising,” he said.

The most important message from this session was a truly multidisciplinary one. Both speakers concluded that rather than continuously opposing each other, urologists and oncologists should work together to treat patients with high-risk prostate cancer.

Share this article

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer